Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non–Small Cell Lung Cancer

被引：0
|
作者：
Mitsugu Ikeda
Tatsuya Ochibe
Masahiro Tohkin
机构：
[1] Nagoya City University,Department of Regulatory Science, Graduate School of Pharmaceutical Sciences
来源：
Therapeutic Innovation & Regulatory Science | 2019年 / 53卷
关键词：
phase 3 clinical trial; systematic review; non—small cell lung cancer; primary endpoint; success rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：324 / 331
页数：7
相关论文
共 50 条
  • [41] Kangai Injection Combined with Platinum-based Chemotherapy for the Treatment of Stage III/IV Non-Small Cell Lung Cancer: A Meta-analysis and Systematic Review of 35 Randomized Controlled Trials
    Li, Hongxiao
    Ji, Yuejin
    Zhang, Shiping
    Gao, Zishan
    Hu, Cheng
    Jiang, Rilei
    Chen, Meijuan
    Li, Guochun
    Zhang, Xu
    JOURNAL OF CANCER, 2019, 10 (21): : 5283 - 5298
  • [42] Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer:: A systematic review of phase III trials
    Barlési, F
    Pujol, JL
    LUNG CANCER, 2005, 49 (03) : 289 - 298
  • [43] Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
    Shi, Liang
    Tang, Junfang
    Tong, Li
    Liu, Zhe
    LUNG CANCER, 2014, 83 (02) : 231 - 239
  • [44] Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines
    Zeng, Fen-Lian
    Xiao, Zheng
    Wang, Cheng-Qiong
    Jiang, Yuan
    Shan, Jing-Li
    Hu, Shan-Shan
    Huang, Xiao-Rong
    Tang, Yu-Hong
    Yao, Xing-Sheng
    Zhang, Tao
    Zeng, Xian-Tao
    Feng, Ji-Hong
    Xiao, Xue
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 75
  • [45] A Systematic Review of Phase II/III Trials of Hypofractionated versus Conventionally Fractionated Radiation Therapy in Stage III Non-Small Cell Lung Cancer Patients
    Tsao, May N.
    Ung, Yee
    Cheung, Patrick
    Poon, Ian
    Louie, Alexander V.
    CANCERS, 2024, 16 (19)
  • [46] Optimal Clinical Target Volume of Radiotherapy Based on Microscopic Extension around the Primary Gross Tumor in Non-Small-Cell Lung Cancer: A Systematic Review
    Tamaki, Yukihisa
    Aibe, Norihiro
    Komiyama, Takafumi
    Nagasaka, Satoshi
    Imagumbai, Toshiyuki
    Itazawa, Tomoko
    Onishi, Hiroshi
    Akimoto, Tetsuo
    Nagata, Yasushi
    Nakayama, Yuko
    CANCERS, 2022, 14 (09)
  • [47] The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
    Zhang, Yue-Lun
    Yuan, Jin-Qiu
    Wang, Kai-Feng
    Fu, Xiao-Hong
    Han, Xiao-Ran
    Threapleton, Diane
    Yang, Zu-Yao
    Mao, Chen
    Tang, Jin-Ling
    ONCOTARGET, 2016, 7 (48) : 78971 - 78979
  • [48] The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
    Ababneh, O.
    Ahmed, Y.
    Syaj, S.
    Hatamleh, Z.
    Saleh, S.
    Zaitoun, A.
    Akhdar, M.
    Ahmad, M. Alsaid
    Al-Shadiafat, R.
    Hamouri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S459 - S460
  • [49] Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
    Zhang, Jian
    Zhang, Weiqing
    Huang, Shaohong
    Li, Hui
    Li, Yun
    Chen, Huiguo
    Wu, Weibing
    Zhou, Wei
    Wang, Cuiping
    Liao, Hongying
    Gu, Lijia
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (05) : 849 - 858
  • [50] The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review
    Kulkarni, Swati
    Vella, Emily T.
    Coakley, Nadia
    Cheng, Susanna
    Gregg, Richard
    Ung, Yee C.
    Ellis, Peter M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 989 - 1002
12345